Nearly two months after Pfizer’s COVID-19 antiviral pill Paxlovid was authorized by the FDA, the drugmaker released final efficacy and safety data for the pill in a study published Feb. 16 in the New England Journal of Medicine.
Read the full post on Becker's Hospital Review - Healthcare News
